Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BWAY Brainsway	$12.86 +1.2%	$11.98	$7.06 ▼ $13.65	$243.00M	1.42	52,427 shs	92,064 shs
CTSO Cytosorbents	$1.13 +4.6%	$1.06	$0.71 ▼ $1.61	$70.92M	1.19	190,791 shs	73,435 shs
CVRX CVRx	$7.24 -6.3%	$6.95	$4.30 ▼ $18.55	$189.24M	1.27	325,320 shs	300,080 shs
SMTI Sanara MedTech	$30.24 -5.3%	$27.64	$23.53 ▼ $39.08	$268.83M	1.26	33,626 shs	51,990 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BWAY Brainsway	+4.18%	+7.26%	+3.84%	+27.25%	+78.87%
CTSO Cytosorbents	+1.89%	+19.73%	+2.86%	+29.36%	+20.67%
CVRX CVRx	+2.80%	+9.15%	+5.03%	+24.72%	-9.71%
SMTI Sanara MedTech	+16.20%	+30.02%	+10.56%	+3.37%	-0.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BWAY Brainsway	3.3136 of 5 stars	2.5	5.0	3.9	0.8	1.9
CTSO Cytosorbents	1.6056 of 5 stars	3.3	2.0	2.0	0.0	0.6
CVRX CVRx	2.7964 of 5 stars	3.4	1.0	2.4	4.2	0.6
SMTI Sanara MedTech	2.1205 of 5 stars	3.5	1.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BWAY Brainsway	3.00	Buy	$18.00	40.00% Upside
CTSO Cytosorbents	2.50	Moderate Buy	$5.50	386.73% Upside
CVRX CVRx	2.86	Moderate Buy	$14.00	93.48% Upside
SMTI Sanara MedTech	3.00	Buy	$49.50	63.69% Upside

Current Analyst Ratings Breakdown

Latest CTSO, BWAY, SMTI, and CVRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	BWAY Brainsway	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $17.00
8/14/2025	BWAY Brainsway	Northland Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$15.00 ➝ $19.00
8/8/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/5/2025	CVRX CVRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00
7/21/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/7/2025	CVRX CVRx	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/9/2025	BWAY Brainsway	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/15/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	CTSO Cytosorbents	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.00 ➝ $1.00
5/15/2025	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$51.00 ➝ $53.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BWAY Brainsway	$41.02M	5.92	$0.26 per share	48.88	$3.31 per share	3.88
CTSO Cytosorbents	$35.60M	1.99	N/A	N/A	$0.18 per share	6.28
CVRX CVRx	$54.65M	3.46	N/A	N/A	$2.22 per share	3.26
SMTI Sanara MedTech	$86.67M	3.10	N/A	N/A	$4.45 per share	6.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BWAY Brainsway	$2.92M	$0.20	64.29	80.36	N/A	9.01%	7.35%	4.72%	N/A
CTSO Cytosorbents	-$20.72M	-$0.17	N/A	N/A	N/A	-25.58%	-111.97%	-29.00%	N/A
CVRX CVRx	-$59.97M	-$2.10	N/A	N/A	N/A	-95.61%	-79.31%	-40.96%	N/A
SMTI Sanara MedTech	-$9.66M	-$1.34	N/A	N/A	N/A	-12.48%	-29.22%	-13.20%	N/A

Latest CTSO, BWAY, SMTI, and CVRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	BWAY Brainsway	$0.07	$0.10	+$0.03	$0.10	$12.34 million	$12.63 million
8/13/2025	Q2 2025	SMTI Sanara MedTech	-$0.33	-$0.23	+$0.10	-$0.23	$25.15 million	$25.83 million
8/7/2025	Q2 2025	CTSO Cytosorbents	-$0.07	-$0.05	+$0.02	$0.03	$9.79 million	$9.62 million
8/4/2025	Q2 2025	CVRX CVRx	-$0.52	-$0.57	-$0.05	-$0.57	$13.22 million	$13.59 million
5/14/2025	Q1 2025	CTSO Cytosorbents	-$0.08	-$0.06	+$0.02	-$0.02	$9.01 million	$8.73 million
5/14/2025	Q1 2025	SMTI Sanara MedTech	-$0.31	-$0.41	-$0.10	-$0.41	$23.48 million	$23.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BWAY Brainsway	N/A	N/A	N/A	N/A	N/A
CTSO Cytosorbents	N/A	N/A	N/A	N/A	N/A
CVRX CVRx	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BWAY Brainsway	N/A	5.03	4.75
CTSO Cytosorbents	1.24	2.34	2.30
CVRX CVRx	0.85	11.99	10.78
SMTI Sanara MedTech	1.18	2.77	2.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BWAY Brainsway	30.11%
CTSO Cytosorbents	32.87%
CVRX CVRx	75.27%
SMTI Sanara MedTech	8.10%

Insider Ownership

Company	Insider Ownership
BWAY Brainsway	19.00%
CTSO Cytosorbents	7.30%
CVRX CVRx	13.90%
SMTI Sanara MedTech	42.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BWAY Brainsway	120	18.90 million	15.31 million	Not Optionable
CTSO Cytosorbents	220	62.76 million	58.18 million	Optionable
CVRX CVRx	160	26.15 million	22.52 million	Optionable
SMTI Sanara MedTech	60	8.89 million	5.10 million	Not Optionable

CTSO, BWAY, SMTI, and CVRX Headlines

Recent News About These Companies

Sanara MedTech Reports Strong Revenue Growth in Q2 2025

August 14 at 9:09 AM | msn.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q2 2025 Earnings Call Transcript

August 14 at 9:09 AM | msn.com

Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript

August 13 at 2:58 PM | seekingalpha.com

Sanara MedTech Sales Jump 28 Percent

August 13 at 9:56 AM | theglobeandmail.com

Sanara MedTech Inc. (SMTI) Reports Q2 Loss, Tops Revenue Estimates

August 13 at 9:26 AM | zacks.com

Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)

August 13 at 7:00 AM | globenewswire.com

Sanara MedTech Inc (SMTI) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 12 at 6:54 PM | finance.yahoo.com

Sanara MedTech (SMTI) Projected to Post Quarterly Earnings on Wednesday

August 12 at 2:21 AM | americanbankingnews.com

Sanara MedTech (NASDAQ:SMTI) investors are sitting on a loss of 12% if they invested three years ago

August 10, 2025 | finance.yahoo.com

Sanara MedTech (SMTI) to Release Earnings on Wednesday

August 6, 2025 | marketbeat.com

Sanara MedTech (NASDAQ:SMTI) Stock Price Down 1.5% - Here's Why

July 18, 2025 | marketbeat.com

Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025

July 15, 2025 | globenewswire.com

Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program

July 14, 2025 | globenewswire.com

Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb

June 9, 2025 | seekingalpha.com

Sanara MedTech Shares Down, Investors Sought For Pilot Program

May 15, 2025 | marketwatch.com

Earnings call transcript: Sanara Medtech Q1 2025 earnings miss forecasts

May 15, 2025 | investing.com

Earnings call transcript: Sanara Medtech Q1 2025 earnings miss forecasts

May 15, 2025 | investing.com

Sanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

May 15, 2025 | finance.yahoo.com

Sanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

May 15, 2025 | finance.yahoo.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO, BWAY, SMTI, and CVRX Company Descriptions

Brainsway NASDAQ:BWAY

$12.86 +0.16 (+1.24%)

Closing price 03:59 PM Eastern

Extended Trading

$12.84 -0.02 (-0.13%)

As of 04:04 PM Eastern

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Cytosorbents NASDAQ:CTSO

$1.13 +0.05 (+4.63%)

Closing price 03:58 PM Eastern

Extended Trading

$1.14 +0.01 (+0.88%)

As of 04:04 PM Eastern

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CVRx NASDAQ:CVRX

$7.24 -0.48 (-6.27%)

Closing price 03:59 PM Eastern

Extended Trading

$7.24 +0.01 (+0.12%)

As of 04:07 PM Eastern

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Sanara MedTech NASDAQ:SMTI

$30.24 -1.68 (-5.26%)

Closing price 03:59 PM Eastern

Extended Trading

$30.39 +0.15 (+0.50%)

As of 04:04 PM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time